$5.15
1.18%
Nasdaq, Sep 17, 04:11 pm EDT. Closed.
ISIN
US17248W3034
Symbol
CING

Cingulate Stock price

$5.15
-0.06 1.15% 1M
-6.51 55.83% 6M
+0.81 18.66% YTD
+1.45 39.19% 1Y
-160.21 96.89% 3Y
-1,062.85 99.52% 5Y
-1,062.85 99.52% 10Y
-1,062.85 99.52% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
+0.06 1.18%
ISIN
US17248W3034
Symbol
CING
Industry

Is Cingulate a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$74.0m
Enterprise Value
$50.7m
Net debt
positive
Cash
$28.4m
Shares outstanding
13.9m
Valuation (TTM | estimate)
P/E
negative
P/S
- | 25.1
EV/Sales
- | 17.2
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
16.6%
Return on Equity
-894.8%
ROCE
-102.0%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $3.0m
EBITDA
$-24.5m
EBIT
$-24.9m
Net Income
$-28.8m
Free Cash Flow
$-20.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-42.2%
EBIT
-39.6%
Net Income
-60.4%
Free Cash Flow
-20.1%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-2.2
FCF per Share
$-1.5
Short interest
10.1%
Employees
14
Rev per Employee
$0.0

Cingulate Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Cingulate forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Cingulate forecast:

Buy
90%
Hold
10%

Financial data from Cingulate

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
129% 129%
-
- Research and Development Expense 8.52 8.52
20% 20%
-
-24 -24
42% 42%
-
- Depreciation and Amortization 0.45 0.45
30% 30%
-
EBIT (Operating Income) EBIT -25 -25
40% 40%
-
Net Profit -29 -29
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cingulate directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cingulate Stock News

Neutral
GlobeNewsWire
about one month ago
KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.
Neutral
GlobeNewsWire
about 2 months ago
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology
Neutral
GlobeNewsWire
3 months ago
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors
More Cingulate News

Company Profile

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.

Head office United States
CEO Dr. Schaffer
Employees 14
Founded 2013
Website www.cingulate.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today